Global pharma company making generics, biosimilars, APIs and OTC/consumer health products across 88 countries.
Price
Market Cap
Sector
Healthcare
Rank
| Line item | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 | FY26 |
|---|---|---|---|---|---|---|---|---|
| LiabilitiesEquity Capital | 83 | 83 | 83 | 83 | 83 | 83 | 84 | 84 |
| Reserves | 15.5k | 17.6k | 19.1k | 23.2k | 28.2k | 33.5k | 35.9k | 37.8k |
| Borrowings | 2.2k | 3.0k | 3.4k | 1.3k | 2.0k | 4.7k | 5.9k | 7.7k |
| Other Liabilities | 5.4k | 5.9k | 7.1k | 7.6k | 8.5k | 9.8k | 12.5k | 11.0k |
| Total Liabilities | 23.2k | 26.6k | 29.7k | 32.2k | 38.8k | 48.0k | 54.4k | 56.6k |
| AssetsFixed Assets | 6.8k | 8.2k | 8.1k | 9.2k | 10.4k | 18.2k | 20.6k | 22.1k |
| CWIP | 1.5k | 1.6k | 1.3k | 1.0k | 1.4k | 2.5k | 2.0k | 1.5k |
| Investments | 2.7k | 2.2k | 2.6k | 5.0k | 4.9k | 4.1k | 4.7k | 5.3k |
| Other Assets | 12.2k | 14.6k | 17.7k | 17.0k | 22.0k | 23.3k | 27.1k | 27.8k |
| Total Assets | 23.2k | 26.6k | 29.7k | 32.2k | 38.8k | 48.0k | 54.4k | 56.6k |
| Line item | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|---|---|
| ActivitiesCash from Operating | 2.9k | 3.0k | 3.6k | 2.8k | 5.9k | 4.5k | 4.6k | 5.7k |
| Cash from Investing | -769 | -495 | -2.3k | -2.6k | -4.1k | -4.0k | -5.8k | -6.4k |
| Cash from Financing | -2.1k | -2.5k | -30 | -242 | -2.7k | -376 | 1.9k | 829 |
| SummaryCapital Expenditure | — | — | — | — | — | — | — | — |
| Free Cash Flow | 2.2k | 2.4k | 2.3k | 1.2k | 4.0k | 1.9k | 1.3k | 2.0k |
| FCF Margin | — | — | — | — | — | — | — | — |
The Earnings Per Share over the last 12 months.
Your assumption of the company's expected yearly EPS growth (e.g., 6 for 6%).
Pre-filled with the lower of median (18.9×) and current (24.1×) PE — the conservative anchor.
The annualized return you aim to achieve. We solve for the price that delivers it, then compare to today's price.
At 2.3% growth and a 19× exit, ₹1211 only delivers your return if you pay ₹444. The price is currently baking in 23% growth.
EPS grows 2.3%/yr for 5 years, then fades to 6% over 2, exits at 19×.
| Year | Growth | EPS (₹) |
|---|---|---|
| FY27 | 2.3% | 51.44 |
| FY28 | 2.3% | 52.62 |
| FY29 | 2.3% | 53.83 |
| FY30 | 2.3% | 55.07 |
| FY31 | 2.3% | 56.33 |
| FY32 | 4.1% ·fade | 58.67 |
| FY33 | 6.0% ·fade | 62.19 |
Methodology: we discount normalized net profit as a proxy for owner earnings (an earnings-power approximation — not full free cash flow). Terminal growth is capped at 6% (≈ nominal GDP) regardless of the required return. This is an analytical tool, not investment advice.
Guides on how to read this kind of business and the numbers that matter.